Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
about
Interactions between kidney disease and diabetes: dangerous liaisonsThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical ExperienceNovel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetesAutomated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies.Factors influencing the effectiveness of glucagon for preventing hypoglycemia.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function.Insulin aspart: a review.The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinomaInsulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?A review of artificial pancreas technologies with an emphasis on bi-hormonal therapyInsulin degludec: pharmacokinetic properties in subjects with hepatic impairmentInsulin degludec: pharmacokinetics in patients with renal impairment.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Diversity in diabetes: the role of insulin aspart.Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Intermediary variables and algorithm parameters for an electronic algorithm for intravenous insulin infusion
P2860
Q26740630-77F774F4-C912-4834-A2D3-88385051B4ABQ26744317-AB8554FA-879D-40C7-BB0F-95C36AC5087FQ26766259-3FA65925-0533-4A3C-A019-6E3AD93D2930Q28085428-733A23D4-C504-496C-84D0-7C3DA3140C0DQ33873106-20675DA3-780A-476B-B83C-77AE5985F1E9Q34243374-D34A92EF-E998-457D-B2D0-FE42342A72BCQ34419950-D9FCFDD3-C7C1-49C8-A05B-9C7B20D57A61Q35671873-F66B9DEE-F7F3-4D0C-BF0A-E0463E107F89Q35684921-2935CCAE-6D9D-44D1-A418-60584C5F4FAAQ36292990-94EF702A-057A-4A31-A265-1D5C49156CFBQ36609772-F8A0EFC0-165B-4CCD-B2CF-A1F4AC1A3CB5Q36706822-E44905A4-2C22-469E-938A-188F4332E53DQ37127547-5713ADCC-8EED-4AA4-AEC4-4520F20E5C0EQ37154369-52BF4FFF-3084-471C-A97F-FEDB836C71E6Q37506417-C797762C-71EB-4086-BB28-8E95204822B2Q37506526-4A53EA01-290E-44DB-8D56-25EE1F5B8FE4Q37721962-2B3DBA15-E9AB-49AE-B94E-6AB5FDEBC62BQ37893108-6AD582F0-0DB2-4073-8D52-5C5E80322BBBQ38028009-9761A264-0285-4A81-BA7B-2E47E3DD4AB3Q38086611-4EF9112F-371D-4D12-9916-3F195AA992ACQ38606170-C4316C0C-B27D-4961-ACD6-93DE04D359F4Q38887939-8C7987BC-0A49-484A-88ED-81F1F14BE6A8Q38970550-731BF194-06CC-4F55-B7EF-92F5D16FE22DQ42599713-4B8E406C-39B3-4547-BDC2-014588181DDB
P2860
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@ast
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@en
type
label
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@ast
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@en
prefLabel
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@ast
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@en
P2093
P2860
P1476
Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
@en
P2093
Gregory Holmes
Lawrence Galitz
William Lyness
P2860
P304
P356
10.1111/J.1365-2125.2005.02476.X
P407
P577
2005-11-01T00:00:00Z